CRISPR Therapeutics (CRSP) has been drawing attention after recent share price moves, with the biotech stock trading near US$54 as of the latest close. Investors are weighing this performance against its gene editing pipeline.
Over the past year, CRISPR Therapeutics has seen its share price ebb, with a recent 7-day share price return down 7.27% and a 30-day move lower by 6.29%, while the 3-year total shareholder return of 27.54% contrasts with a 1-year total shareholder return that declined 15.18%. This suggests that earlier enthusiasm has cooled and investors are reassessing both growth potential and risk around the current US$54.09 level.
Scan beyond CRISPR Therapeutics and explore other beaten-down opportunities with the 32 high quality undervalued stocks.
CRISPR Therapeutics trades well below both analyst targets and an indicated intrinsic value, yet recent losses and ongoing net income pressure keep investors wary. Is that discount a cushion or a warning sign as you look at valuation next?
Most Popular Narrative: 38% Undervalued
At a last close of $54.09 versus a narrative fair value of $87.56, CRISPR Therapeutics is framed as materially discounted. This puts a lot of weight on how its late stage pipeline performs over the next few years.
Expansion of CASGEVY to pediatric patients as young as 2 years old and a growing base of more than 75 authorized treatment centers worldwide increase the pool of eligible sickle cell and beta thalassemia patients, which can support higher future revenue and improve earnings leverage as fixed infrastructure is used more fully.
See why 6 investors see CRISPR Therapeutics as 38% undervalued.
Result: Fair Value of $87.56 (UNDERVALUED)
Still, the narrative for CRISPR Therapeutics can unravel quickly if CASGEVY uptake fails to offset ongoing losses, or if further funding drives heavier dilution than expected.
Find out about the key risks to this CRISPR Therapeutics narrative.
Another View: How Multiples Frame CRISPR Therapeutics
CRISPR Therapeutics looks inexpensive on some models, yet its P/B of 3x tells a different story. That level is higher than the US Biotechs industry average of 2.1x, even though it sits well below a peer average around 11x. Is that a fair premium or a valuation trap for a loss making business?
Before leaning on that comparison, it helps to check how the detailed valuation compares with these headline ratios. You can do that through the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Sentiment on CRISPR Therapeutics in this piece is mixed, so move quickly and stress test the numbers yourself before views harden. To see what investors are optimistic about, review the 2 key rewards.
Looking for more CRISPR Therapeutics sized opportunities?
If CRISPR Therapeutics has you thinking harder about risk, reward, and timing, use that momentum and widen your search before the next move passes you by.
- Spot potential turnaround stories early and scan the 7 elite penny stocks with strong financials that combine smaller market caps with more robust financial profiles than many expect.
- Zero in on value-focused opportunities by filtering for 16 high quality undiscovered gems that already pair solid fundamentals with less crowded ownership.
- Prioritize staying power in tougher markets and review a list of solid balance sheet and fundamentals (25 results) that can help you focus on resilience before sentiment shifts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com